Media stories about Eli Lilly and (NASDAQ:LLY
) have been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Eli Lilly and earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.174976601571 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

TRADEMARK VIOLATION NOTICE: “Eli Lilly and (LLY ) Receiving Somewhat Favorable Press Coverage, Analysis Finds” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.watchlistnews.com/eli-lilly-and-lly-receiving-somewhat-favorable-press-coverage-analysis-finds/1676443.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Insider Buying and Selling by Quarter for Eli Lilly and (NASDAQ:LLY
)

Receive News & Ratings for Eli Lilly and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co and related companies with Analyst Ratings Network's FREE daily email newsletter.